Replimune, INC.
Oncolytic immunotherapies for cancer treatment
Visit website ContactClaim & upgrade this listingContact details are protected Something wrong? Suggest a correction
Replimune develops oncolytic immunotherapies for cancer patients, with treatments intended to stimulate tumor-specific immune responses. Its FDA-approved therapy, TUDRIQEV, is used with nivolumab for advanced melanoma following progression on an anti-PD-1-containing regimen. The company also evaluates investigational therapies for solid tumors in clinical trials.
At a Glance
Replimune, INC. is an American manufacturer based in Woburn, MA.
- Where
- Woburn, MA
